Combining neratinib with CDK4/6, mTOR and MEK inhibitors in models of HER2-positive cancer.

CONCLUSION: Taken together, our results provide strong preclinical evidence for combining neratinib with CDK4/6, mTOR and MEK inhibitors for the treatment of HER2+ cancer.
PMID: 33414137 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 7, 2021 Category: Cancer & Oncology Authors: Zhao M, Scott S, Evans KW, Yuca E, Saridogan T, Zheng X, Wang H, Korkut A, Cruz Pico CX, Demirhan ME, Kirby B, Kopetz S, Diala I, Lalani AS, Piha-Paul S, Meric-Bernstam F Tags: Clin Cancer Res Source Type: research